C4 Therapeutics (CCCC) Stock Forecast, Price Target & Predictions
CCCC Stock Forecast
C4 Therapeutics stock forecast is as follows: an average price target of $13.50 (represents a 233.33% upside from CCCC’s last price of $4.05) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CCCC Price Target
The average price target for C4 Therapeutics (CCCC) is $13.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $9.00. This represents a potential 233.33% upside from CCCC's last price of $4.05.
CCCC Analyst Ratings
According to 4 Wall Street analysts, C4 Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CCCC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
C4 Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | Etzer Darout | BMO Capital | $20.00 | $6.87 | 191.12% | 393.83% |
| Jan 03, 2023 | - | Wells Fargo | $9.00 | $6.31 | 42.63% | 122.22% |
| Apr 28, 2022 | - | Credit Suisse | $10.00 | $8.85 | 12.99% | 146.91% |
| Apr 11, 2022 | Chi Fong | Bank of America Securities | $15.00 | $8.01 | 87.27% | 270.37% |
The latest C4 Therapeutics stock forecast, released on Sep 19, 2024 by Etzer Darout from BMO Capital, set a price target of $20.00, which represents a 191.12% increase from the stock price at the time of the forecast ($6.87), and a 393.83% increase from CCCC last price ($4.05).
C4 Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $20.00 | $20.00 |
| Last Closing Price | $4.05 | $4.05 | $4.05 |
| Upside/Downside | -100.00% | 393.83% | 393.83% |
In the current month, the average price target of C4 Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to C4 Therapeutics's last price of $4.05. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Dec 13, 2023 | Piper Sandler | - | Buy | Upgrade |
| Feb 24, 2023 | Credit Suisse | Underperform | Neutral | Upgrade |
| Jan 03, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Apr 28, 2022 | Credit Suisse | - | Underperform | Initialise |
C4 Therapeutics's last stock rating was published by BMO Capital on Sep 19, 2024. The company gave CCCC a "Outperform" rating, the same as its previous rate.
C4 Therapeutics Financial Forecast
C4 Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $2.66M | $3.76M | $2.85M | $6.75M | $13.83M | $7.65M | $20.08M | $8.50M | $9.78M | $7.43M | $8.26M | $8.45M |
| Avg Forecast | $5.60M | $5.60M | $5.60M | $80.60M | $5.11M | $5.90M | $4.78M | $11.99M | $3.20M | $5.28M | $6.41M | $5.46M | $9.87M | $8.45M | $7.64M | $7.81M | $7.41M | $7.61M | $6.29M | $3.87M | $8.00M | $6.07M |
| High Forecast | $6.55M | $6.55M | $6.55M | $94.27M | $5.97M | $5.94M | $4.78M | $11.99M | $7.17M | $5.37M | $7.50M | $6.39M | $11.55M | $8.45M | $7.64M | $7.81M | $7.41M | $7.61M | $6.29M | $3.87M | $8.00M | $6.07M |
| Low Forecast | $4.95M | $4.95M | $4.95M | $71.17M | $4.51M | $5.87M | $4.78M | $11.99M | $735.29K | $5.18M | $5.66M | $4.82M | $8.72M | $8.45M | $7.64M | $7.81M | $7.41M | $7.61M | $6.29M | $3.87M | $8.00M | $6.07M |
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.42% | 0.69% | 0.29% | 0.80% | 1.81% | 0.98% | 2.71% | 1.12% | 1.55% | 1.92% | 1.03% | 1.39% |
C4 Therapeutics's average Quarter revenue forecast for Sep 23 based on 8 analysts is $5.28M, with a low forecast of $5.18M, and a high forecast of $5.37M. CCCC's average Quarter revenue forecast represents a 98.06% increase compared to the company's last Quarter revenue of $2.66M (Jun 23).
C4 Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-27.81M | $-35.32M | $-34.17M | $-36.06M | $-30.99M | $-26.44M | $-30.79M | $-14.80M | $-23.81M | $-21.66M | $-19.99M | $-20.50M | $-21.23M |
| Avg Forecast | $-5.60M | $-5.60M | $-5.60M | $-80.60M | $-5.11M | $-5.90M | $-4.78M | $-37.67M | $-3.20M | $-5.28M | $-6.41M | $-34.25M | $-24.69M | $-8.45M | $-7.64M | $-27.07M | $-7.41M | $-7.61M | $-6.29M | $-24.43M | $-8.00M | $-386.25M |
| High Forecast | $-4.95M | $-4.95M | $-4.95M | $-71.17M | $-4.51M | $-5.87M | $-4.78M | $-30.14M | $-735.29K | $-5.18M | $-5.66M | $-27.40M | $-19.75M | $-8.45M | $-7.64M | $-21.66M | $-7.41M | $-7.61M | $-6.29M | $-19.54M | $-8.00M | $-309.00M |
| Low Forecast | $-6.55M | $-6.55M | $-6.55M | $-94.27M | $-5.97M | $-5.94M | $-4.78M | $-45.21M | $-7.17M | $-5.37M | $-7.50M | $-41.10M | $-29.62M | $-8.45M | $-7.64M | $-32.49M | $-7.41M | $-7.61M | $-6.29M | $-29.31M | $-8.00M | $-463.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.27% | 5.51% | 1.00% | 1.46% | 3.67% | 3.46% | 1.14% | 2.00% | 3.13% | 3.44% | 0.82% | 2.56% | 0.05% |
undefined analysts predict CCCC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than C4 Therapeutics's previous annual EBITDA (undefined) of $NaN.
C4 Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $-27.04M | $-35.92M | $-33.94M | $-36.08M | $-31.43M | $-27.44M | $-31.87M | $-16.20M | $-24.68M | $-22.58M | $-20.97M | $-21.80M | $-21.84M |
| Avg Forecast | $-30.16M | $-28.18M | $-29.84M | $13.29M | $-33.91M | $-26.39M | $-25.37M | $-38.69M | $-47.83M | $-46.18M | $-47.65M | $-35.17M | $-26.13M | $-48.86M | $-47.62M | $-27.80M | $-39.65M | $-39.45M | $-40.60M | $-25.63M | $-36.46M | $-397.26M |
| High Forecast | $-25.57M | $-23.90M | $-25.30M | $13.57M | $-24.11M | $-22.37M | $-21.51M | $-30.95M | $-31.41M | $-33.59M | $-40.40M | $-28.14M | $-20.90M | $-48.86M | $-47.62M | $-22.24M | $-39.65M | $-39.45M | $-40.60M | $-20.50M | $-36.46M | $-317.81M |
| Low Forecast | $-36.81M | $-34.40M | $-36.41M | $12.74M | $-44.46M | $-32.20M | $-30.96M | $-46.43M | $-62.11M | $-58.08M | $-58.15M | $-42.21M | $-31.35M | $-48.86M | $-47.62M | $-33.36M | $-39.65M | $-39.45M | $-40.60M | $-30.76M | $-36.46M | $-476.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.59% | 0.75% | 0.96% | 1.38% | 0.64% | 0.58% | 1.15% | 0.41% | 0.63% | 0.56% | 0.82% | 0.60% | 0.05% |
C4 Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CCCC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
C4 Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $10.53M | $10.31M | $10.95M | $10.49M | $9.58M | $9.89M | $12.82M | $8.78M | $8.45M | $8.61M | $7.41M | $6.73M | $2.86M |
| Avg Forecast | $5.60M | $5.60M | $5.60M | $80.57M | $5.10M | $5.90M | $4.78M | $11.99M | $3.20M | $5.27M | $6.41M | $5.46M | $9.87M | $7.82M | $7.07M | $7.22M | $6.85M | $7.04M | $5.82M | $3.58M | $7.40M | $5.61M |
| High Forecast | $6.55M | $6.55M | $6.55M | $94.23M | $5.97M | $5.93M | $4.78M | $11.99M | $7.17M | $5.37M | $7.50M | $6.39M | $11.54M | $7.82M | $7.07M | $7.22M | $6.85M | $7.04M | $5.82M | $3.58M | $7.40M | $5.61M |
| Low Forecast | $4.94M | $4.94M | $4.94M | $71.15M | $4.51M | $5.86M | $4.78M | $11.99M | $735.01K | $5.18M | $5.66M | $4.82M | $8.71M | $7.82M | $7.07M | $7.22M | $6.85M | $7.04M | $5.82M | $3.58M | $7.40M | $5.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.00% | 1.61% | 2.00% | 1.06% | 1.23% | 1.40% | 1.78% | 1.28% | 1.20% | 1.48% | 2.07% | 0.91% | 0.51% |
C4 Therapeutics's average Quarter SG&A projection for Dec 23 is $3.20M, based on 6 Wall Street analysts, with a range of $735.01K to $7.17M. The forecast indicates a -69.59% fall compared to CCCC last annual SG&A of $10.53M (Sep 23).
C4 Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.55 | $-0.73 | $-0.69 | $-0.74 | $-0.64 | $-0.56 | $-0.65 | $-0.33 | $-0.51 | $-0.51 | $-0.49 | $-0.53 | $-0.66 |
| Avg Forecast | $-0.43 | $-0.40 | $-0.43 | $0.19 | $-0.49 | $-0.38 | $-0.36 | $-0.36 | $-0.69 | $-0.66 | $-0.68 | $-0.75 | $-0.74 | $-0.71 | $-0.69 | $-0.62 | $-0.58 | $-0.57 | $-0.59 | $-0.63 | $-0.53 | $-0.63 |
| High Forecast | $-0.37 | $-0.34 | $-0.36 | $0.19 | $-0.35 | $-0.32 | $-0.31 | $-0.31 | $-0.45 | $-0.48 | $-0.58 | $-0.63 | $-0.63 | $-0.71 | $-0.69 | $-0.62 | $-0.58 | $-0.57 | $-0.59 | $-0.63 | $-0.53 | $-0.63 |
| Low Forecast | $-0.53 | $-0.49 | $-0.52 | $0.18 | $-0.64 | $-0.46 | $-0.44 | $-0.45 | $-0.89 | $-0.83 | $-0.84 | $-0.91 | $-0.91 | $-0.71 | $-0.69 | $-0.62 | $-0.58 | $-0.57 | $-0.59 | $-0.63 | $-0.53 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.83% | 1.07% | 0.92% | 0.99% | 0.90% | 0.81% | 1.05% | 0.57% | 0.89% | 0.86% | 0.78% | 1.01% | 1.05% |
According to undefined Wall Street analysts, C4 Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CCCC previous annual EPS of $NaN (undefined).
C4 Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $15.00 | 1090.48% | Buy |
| STTK | Shattuck Labs | $1.11 | $12.00 | 981.08% | Hold |
| PRLD | Prelude Therapeutics | $0.96 | $6.25 | 551.04% | Sell |
| CCCC | C4 Therapeutics | $4.05 | $13.50 | 233.33% | Buy |
| ARVN | Arvinas | $22.69 | $71.00 | 212.91% | Buy |
| RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
| FHTX | Foghorn Therapeutics | $7.86 | $16.33 | 107.76% | Buy |
| NRIX | Nurix Therapeutics | $22.64 | $32.20 | 42.23% | Buy |
| EWTX | Edgewise Therapeutics | $31.95 | $45.00 | 40.85% | Buy |
| KYMR | Kymera Therapeutics | $44.05 | $51.50 | 16.91% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |